FocalTherics (NASDAQ:FOCL) Given Average Recommendation of “Hold” by Analysts

FocalTherics (NASDAQ:FOCL) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $7.75.

Several equities research analysts have recently commented on FOCL shares. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research note on Tuesday, August 25th. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Finally, Piper Sandler restated a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research note on Friday, August 14th.

FocalTherics Price Performance

Shares of FOCL stock opened at $4.15 on Tuesday. The firm has a market cap of $155.75 million, a PE ratio of -4.03 and a beta of -0.07. FocalTherics has a 52-week low of $1.75 and a 52-week high of $6.40. The firm has a 50-day moving average of $5.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 1.38.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million for the quarter. Analysts expect that FocalTherics will post -0.82 earnings per share for the current fiscal year.

Insider Activity

In other FocalTherics news, Director Lance Willsey acquired 50,000 shares of the stock in a transaction on Friday, August 14th. The shares were bought at an average price of $4.75 per share, with a total value of $237,500.00. Following the acquisition, the director owned 1,291,780 shares of the company’s stock, valued at $6,135,955. This trade represents a 4.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David R. Horn bought 10,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were acquired at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at $47,500. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 116,000 shares of company stock valued at $551,000 over the last ninety days. 10.10% of the stock is currently owned by company insiders.

Institutional Trading of FocalTherics

Institutional investors have recently modified their holdings of the business. Rock Springs Capital Management LP lifted its holdings in FocalTherics by 7.1% in the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares during the period. Flax Pond Capital LLC acquired a new position in shares of FocalTherics during the 4th quarter worth $2,623,000. Leonteq Securities AG acquired a new position in shares of FocalTherics during the 4th quarter worth $313,000. Kovack Advisors Inc. purchased a new position in shares of FocalTherics in the 4th quarter valued at about $53,000. Finally, Lido Advisors LLC purchased a new position in shares of FocalTherics in the 1st quarter valued at about $40,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.